Clinical trials: Antidepressant
Depressive Disorder, Pregnancy
EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy
The purpose of this study is to assess the effectiveness of the EnBrace HR prenatal supplement in preventing depression in women with a history of depression who have decided to stop taking antidepressants during their pregnancy…
- Trial name
- NCT02676882
- Testing
- EnBrace HR
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Psychotic Depression
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
- Trial name
- Abilify (NCT00556140)
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Post-Traumatic Stress Disorder
Comparison of Two Treatments for Post-Traumatic Stress Disorder
This study will compare the short- and long-term effectiveness of two different treatments for people with post-traumatic stress disorder.
- Trial name
- NCT00127673
- Testing
- Sertraline, Cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Case Western Reserve University
Depression
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
- Trial name
- NCT00200902
- Testing
- Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Interpersonal Clinical Interaction (ICI)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of California, Los Angeles
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
Treatment Study of Bipolar Depression
The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.
- Trial name
- NCT00947791
- Testing
- ketamine, midazolam
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bipolar Depression
Ceftriaxone in the Management of Bipolar Depression
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to…
- Trial name
- NCT00566111
- Testing
- ceftriaxone, Saline solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Depression
Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting
This was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression.
- Trial name
- NCT01610063
- Testing
- Pharmacogenomic algorithm
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Chronic Low Back Pain
Chronic Low Back Pain Research Project
The purpose of this study is to determine whether gabapentin is efficacious as an analgesic for chronic low back pain.
- Trial name
- NCT00108550
- Testing
- gabapentin
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Mechanisms of Antidepressant Non-Response in Late-Life Depression
This project seeks to elucidate the mechanisms by which antidepressant medications have limited efficacy in Late Life Depression (LLD) in order to develop new treatment interventions for this prevalent and disabling illness.
- Trial name
- NCT01931202
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Contact: Developing New Clinical Management Strategies
The goal of this study is to develop new methods of administering antidepressant medications that will result in improved drug/placebo separation in randomized controlled trials (RCTs) for Major Depressive Disorder (MDD) and…
- Trial name
- NCT03812588
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Brain Imaging Techniques That Predict Antidepressant Responsiveness
Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine treatment and do changes in selective structures, such as the amygdala, predict treatment response?
- Trial name
- WyethKolden (NCT00909155)
- Testing
- Venlafaxine ERT, Fluoxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)